Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Tcr2 Therapeutics Inc is a biotechnology business based in the US. Tcr2 Therapeutics shares (TCRR) are listed on the NASDAQ and all prices are listed in US Dollars. Tcr2 Therapeutics employs 145 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.94 |
|---|---|
| 52-week range | $2.07 - $19.03 |
| 50-day moving average | $2.41 |
| 200-day moving average | $4.65 |
| Wall St. target price | $13.89 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.81 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.94 from 2022-06-29
| 1 week (2022-06-23) | 4.63% |
|---|---|
| 1 month (2022-05-26) | N/A |
| 3 months (2022-03-30) | 10.53% |
| 6 months (2021-12-30) | -38.62% |
| 1 year (2021-06-30) | -82.08% |
|---|---|
| 2 years (2020-06-30) | -80.86% |
| 3 years (2019-06-28) | 14.31 |
| 5 years (2017-06-26) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.96% |
| Return on equity TTM | -35.51% |
| Profit margin | 0% |
| Book value | $6.62 |
| Market capitalisation | $110.2 million |
TTM: trailing 12 months
We're not expecting Tcr2 Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Tcr2 Therapeutics's shares have ranged in value from as little as $2.065 up to $19.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tcr2 Therapeutics's is 2.197. This would suggest that Tcr2 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
TCR2 Therapeutics Inc. , a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.